PORFIDO FRANK L. 4
4 · TYME TECHNOLOGIES, INC. · Filed Sep 16, 2022
Insider Transaction Report
Form 4
PORFIDO FRANK L.
Chief Financial Officer
Transactions
- Disposition to Issuer
Common Stock
2022-09-16−10,000→ 0 total - Disposition to Issuer
Employee Stock Option - Option to buy
2022-09-16−396,800→ 0 totalExercise: $0.32Exp: 2032-04-22→ Common Stock (396,800 underlying) - Disposition to Issuer
Employee Stock Option - Option to buy
2022-09-16−725,000→ 0 totalExercise: $1.43Exp: 2031-06-14→ Common Stock (725,000 underlying)
Footnotes (3)
- [F1]Disposed of pursuant to the merger agreement between the issuer and Syros Pharmaceuticals, Inc. ("Syros") in exchange for 438 shares of Syros common stock having a market value of $7.30 per share at the close of trading on September 15, 2022, the last trading day immediately preceding the effective time of the merger, but after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"), with cash paid in lieu of fractional shares.
- [F2]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 31,769 shares of Syros common stock for $32.63 per share, after giving effect to the Reverse Split.
- [F3]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 17,387 shares of Syros common stock for $7.30 per share, after giving effect to the Reverse Split.